版权说明 操作指南
首页 > 成果 > 详情

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhang, Yan;Li, Jie;Li, Xi;Geng, Qianshuang;Xie, Yuqin;...
通讯作者:
Ma, YM;Wei, MX
作者机构:
[Ma, YM; Ma, Yanmei; Zhang, Yan] Changzhi Med Coll, Heji Hosp, Dept Hematol, Changzhi 046000, Shanxi, Peoples R China.
[Li, Jie] Hunan Univ Chinese Med, Liuyang Hosp Tradit Chinese Med, Dept Oncol & Hematol, Changsha 410300, Hunan, Peoples R China.
[Li, Xi] Changzhi Med Coll, Heping Hosp, Dept Nephrol, Changzhi 046000, Shanxi, Peoples R China.
[Wei, Mingxia; Wei, MX; Xie, Yuqin; Zhang, Guoxiang; Geng, Qianshuang] Changzhi Med Coll, Heping Hosp, Dept Hematol, Changzhi 046000, Shanxi, Peoples R China.
通讯机构:
[Wei, MX ; Ma, YM ] C
Changzhi Med Coll, Heji Hosp, Dept Hematol, Changzhi 046000, Shanxi, Peoples R China.
Changzhi Med Coll, Heping Hosp, Dept Hematol, Changzhi 046000, Shanxi, Peoples R China.
语种:
英文
期刊:
Systematic Reviews
ISSN:
2046-4053
年:
2024
卷:
13
期:
1
页码:
1-14
基金类别:
This research was supported by the Key Research and Development Project of Science and Technology Department of Liuyang (K23011137) and the Heji Hospital of Changzhi Medical College “2220 Research Incubation Program” (No.202203).
机构署名:
本校为第一机构
摘要:
Immunosuppressive therapy (IST) is the first choice for severe aplastic anemia (SAA) patients with hematopoietic stem cell transplantation (HSCT) limitation, and the main factor limiting its efficacy is too few residual hematopoietic stem/progenitor cells (HSPC). Eltrombopag (EPAG), as a small molecule thrombopoietin receptor agonist, can stimulate the proliferation of residual HSPC and restore the bone marrow hematopoietic function of patients. In recent years, many studies have observed the efficacy and safety of IST combined with EPAG in the...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com